{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T19:19:59Z","timestamp":1790191199090,"version":"4.1.0"},"reference-count":50,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,1,28]],"date-time":"2020-01-28T00:00:00Z","timestamp":1580169600000},"content-version":"unspecified","delay-in-days":27,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000659","name":"Research Trainees Coordinating Centre","doi-asserted-by":"publisher","award":["ICA-CDRF-2017-03-067"],"award-info":[{"award-number":["ICA-CDRF-2017-03-067"]}],"id":[{"id":"10.13039\/501100000659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2020,1,10]]},"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myeloma, a blood cancer originating from plasma cells, is the most common indication for autologous stem cell transplantation (SCT). Patients with myeloma undergoing autologous SCT (ASCT) experience treatment-related morbidity and reduction in function and well-being for many months post-treatment. Interventions targeting physical functioning delivered prior to and during SCT have shown promising results in mixed haematological populations and may offer a non-pharmacological solution to physically optimising and preparing patients for SCT. The aim of this study is to investigate the feasibility of a physiotherapist-led exercise intervention as an integral part of the myeloma ASCT pathway at a UK tertiary centre.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>PERCEPT is a single-site, pilot randomised controlled trial of an exercise intervention embedded within the myeloma ASCT pathway, compared with usual care. The primary study end points will be feasibility measures of study and intervention delivery including recruitment rates, acceptability of intervention, study completion rate and any adverse events. Secondary end points will evaluate differences between the exercise intervention group and the usual care control group in cancer-related fatigue, quality of life, functional capacity (6\u2009min walk test; handheld dynamometry; a timed sit-to-stand test) and objective and self-reported physical activity. Outcomes will be assessed at four time points, approximately 6\u20138 weeks prior to SCT, on\/around day of SCT, on discharge from SCT hospital admission and 12 weeks post-discharge. The exercise intervention comprises of partly supervised physiotherapist-led aerobic and resistance exercise including behaviour change techniques to promote change in exercise behaviour. The primary outcomes from the trial will be summarised as percentages or mean values with 95% CIs. Group differences for secondary outcomes at each time point will be analysed using appropriate statistical models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study has NHS REC approval (Camden and Kings Cross, 19\/LO\/0204). Results will be disseminated through publication and presentations at haematology and rehabilitation-related meetings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"ISRCTN15875290\">ISRCTN15875290<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2019-033176","type":"journal-article","created":{"date-parts":[[2020,1,30]],"date-time":"2020-01-30T05:06:16Z","timestamp":1580360776000},"page":"e033176","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":22,"title":["PERCEPT myeloma: a protocol for a pilot randomised controlled trial of exercise prehabilitation before and during autologous stem cell transplantation in patients with multiple myeloma"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7572-2540","authenticated-orcid":false,"given":"Orla","family":"McCourt","sequence":"first","affiliation":[{"name":"Therapies & Rehabilitation, University College London Hospitals NHS Foundation Trust, London, UK"},{"name":"Research Department of Haematology, Cancer Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Fisher","sequence":"additional","affiliation":[{"name":"Research Department of Behavoural Science and Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gita","family":"Ramdharry","sequence":"additional","affiliation":[{"name":"Queen Square Centre for Neuromuscular Diseases, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L","family":"Roberts","sequence":"additional","affiliation":[{"name":"Research Department of Behavoural Science and Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Land","sequence":"additional","affiliation":[{"name":"Research Department of Behavoural Science and Health, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Rabin","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwee","family":"Yong","sequence":"additional","affiliation":[{"name":"Research Department of Haematology, Cancer Institute, University College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"key":"2025121407452284000_10.1.e033176.1","unstructured":"Haematological Malignancy Research Network (HMRN) . Prevalence, 2019. Available: https:\/\/www.hmrn.org\/statistics\/prevalence [Accessed Jun 2019]."},{"key":"2025121407452284000_10.1.e033176.2","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2014.00241","article-title":"Therapeutic advancements in multiple myeloma","volume":"4","author":"Gozzetti","year":"2014","journal-title":"Front Oncol"},{"key":"2025121407452284000_10.1.e033176.3","unstructured":"Myeloma UK . Symptoms and complications. Available: https:\/\/www.myeloma.org.uk\/information\/symptoms-and-complications\/ [Accessed 18 Apr]."},{"key":"2025121407452284000_10.1.e033176.4","unstructured":"Cancer Research UK . Myeloma statistics, 2015. Available: http:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/myeloma#heading-Zero [Accessed Jun 2019]."},{"key":"2025121407452284000_10.1.e033176.5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/2040620718761776","article-title":"The evolution of stem-cell transplantation in multiple myeloma","volume":"9","author":"Mahajan","year":"2018","journal-title":"Ther Adv Hematol"},{"key":"2025121407452284000_10.1.e033176.6","unstructured":"NHS Commissioning Board . Clinical commissioning policy: haematopoietic stem cell transplantation England. NHS Commissioning Board, 2013."},{"key":"2025121407452284000_10.1.e033176.7","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.086"},{"key":"2025121407452284000_10.1.e033176.8","unstructured":"NHS England . Clinical commissioning policy: haematolopoietic stem cell transplantation (HSCT): revised (All ages). England, 2015."},{"key":"2025121407452284000_10.1.e033176.9","unstructured":"British Society of Blood and Marrow Transplantation . 2016 activity, 2016. Available: http:\/\/www.bsbmt.org\/activity\/2016\/ [Accessed Jun 2019]."},{"key":"2025121407452284000_10.1.e033176.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07992.x"},{"key":"2025121407452284000_10.1.e033176.11","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1200\/JCO.18.01006","article-title":"Patient-reported outcome results from the open-label, randomized phase III myeloma X trial evaluating salvage autologous stem-cell transplantation in relapsed multiple myeloma","volume":"37","author":"Ahmedzai","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025121407452284000_10.1.e033176.12","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","author":"Snowden","year":"2017","journal-title":"Br J Haematol"},{"key":"2025121407452284000_10.1.e033176.13","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-319","article-title":"Perceived benefits and barriers to exercise for recently treated patients with multiple myeloma: a qualitative study","volume":"13","author":"Craike","year":"2013","journal-title":"BMC Cancer"},{"key":"2025121407452284000_10.1.e033176.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2008.09.008"},{"key":"2025121407452284000_10.1.e033176.15","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705917"},{"key":"2025121407452284000_10.1.e033176.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2013.01.001"},{"key":"2025121407452284000_10.1.e033176.17","doi-asserted-by":"publisher","DOI":"10.2522\/ptj.20120181"},{"key":"2025121407452284000_10.1.e033176.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2011.08.011"},{"key":"2025121407452284000_10.1.e033176.19","doi-asserted-by":"crossref","DOI":"10.1186\/s12935-018-0553-8","article-title":"Allogeneic stem-cell transplantation for multiple myeloma: a systematic review and meta-analysis from 2007 to 2017","volume":"18","author":"Yin","year":"2018","journal-title":"Cancer Cell Int"},{"key":"2025121407452284000_10.1.e033176.20","doi-asserted-by":"publisher","DOI":"10.1097\/00002820-200310000-00012"},{"key":"2025121407452284000_10.1.e033176.21","doi-asserted-by":"publisher","DOI":"10.1188\/08.ONF.E53-E61"},{"key":"2025121407452284000_10.1.e033176.22","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1188\/12.ONF.468-477","article-title":"Effects of exercise on fatigue, sleep, and performance: a randomized trial","volume":"39","author":"Coleman","year":"2012","journal-title":"Oncol Nurs Forum"},{"key":"2025121407452284000_10.1.e033176.23","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-13-31","article-title":"A mixed exercise training programme is feasible and safe and may improve quality of life and muscle strength in multiple myeloma survivors","volume":"13","author":"Groeneveldt","year":"2013","journal-title":"BMC Cancer"},{"key":"2025121407452284000_10.1.e033176.24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021333","article-title":"Is it feasible to conduct a randomised controlled trial of pretransplant exercise (prehabilitation) for patients with multiple myeloma awaiting autologous haematopoietic stem cell transplantation? Protocol for the PREeMPT study","volume":"8","author":"Keen","year":"2018","journal-title":"BMJ Open"},{"key":"2025121407452284000_10.1.e033176.25","unstructured":"Macmillan Cancer Support . Impact Briefs: cancer clinical nurse specialists, 2012. Available: https:\/\/www.macmillan.org.uk\/documents\/aboutus\/commissioners\/clinicalnursespecialistsanevidencereview2012.pdf [Accessed Nov 2019]."},{"key":"2025121407452284000_10.1.e033176.26","first-page":"307","article-title":"The effects of training on heart rate; a longitudinal study","volume":"35","author":"Karvonen","year":"1957","journal-title":"Ann Med Exp Biol Fenn"},{"key":"2025121407452284000_10.1.e033176.27","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-198205000-00012"},{"key":"2025121407452284000_10.1.e033176.28","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000121945.36635.61"},{"key":"2025121407452284000_10.1.e033176.29","unstructured":"Department of Health & Social Care . Start active, stay active: a report of physical activity from the four home countries. Chief Medical Officers, 2011."},{"key":"2025121407452284000_10.1.e033176.30","first-page":"CD010192","article-title":"Interventions for promoting habitual exercise in people living with and beyond cancer","volume":"9","author":"Bourke","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121407452284000_10.1.e033176.31","first-page":"Cd010192","article-title":"Interventions for promoting habitual exercise in people living with and beyond cancer","volume":"9","author":"Turner","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121407452284000_10.1.e033176.32","doi-asserted-by":"crossref","DOI":"10.1186\/1741-7015-11-75","article-title":"Are behavioral interventions effective in increasing physical activity at 12 to 36 months in adults aged 55 to 70 years? A systematic review and meta-analysis","volume":"11","author":"Hobbs","year":"2013","journal-title":"BMC Med"},{"key":"2025121407452284000_10.1.e033176.33","doi-asserted-by":"publisher","DOI":"10.1007\/s12160-013-9486-6"},{"key":"2025121407452284000_10.1.e033176.34","unstructured":"Macmillan Cancer Support . Physical activity resources, 2019. Available: https:\/\/www.macmillan.org.uk\/about-us\/health-professionals\/programmes-and-services\/physical-activity\/resources.html [Accessed Jul 2019]."},{"key":"2025121407452284000_10.1.e033176.35","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-1-79","article-title":"The functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation","volume":"1","author":"Webster","year":"2003","journal-title":"Health Qual Life Outcomes"},{"key":"2025121407452284000_10.1.e033176.36","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"2025121407452284000_10.1.e033176.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.022"},{"key":"2025121407452284000_10.1.e033176.38","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700672"},{"key":"2025121407452284000_10.1.e033176.39","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/bmt.2011.107","article-title":"Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30","volume":"47","author":"Grulke","year":"2012","journal-title":"Bone Marrow Transplant"},{"key":"2025121407452284000_10.1.e033176.40","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90143.x"},{"key":"2025121407452284000_10.1.e033176.41","doi-asserted-by":"publisher","DOI":"10.1249\/01.MSS.0000078924.61453.FB"},{"key":"2025121407452284000_10.1.e033176.42","doi-asserted-by":"publisher","DOI":"10.1097\/00006199-200005000-00007"},{"key":"2025121407452284000_10.1.e033176.43","unstructured":"Beecham J , Knapp M . Costing psychiatric interventions. In: Thornicroft G , ed. Measuring mental health needs. 2nd edn. Gaskell, 2001: 200\u201324."},{"key":"2025121407452284000_10.1.e033176.44","first-page":"811","article-title":"Validation of the functional assessment of chronic illness therapy fatigue scale relative to other instrumentation in patients with rheumatoid arthritis","volume":"32","author":"Cella","year":"2005","journal-title":"J Rheumatol"},{"key":"2025121407452284000_10.1.e033176.45","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-8-79","article-title":"Minimal important differences and response shift in health-related quality of life; a longitudinal study in patients with multiple myeloma","volume":"8","author":"Kvam","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2025121407452284000_10.1.e033176.46","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.13316","article-title":"Estimation of minimally important differences and responder definitions for EORTC QLQ\u2010MY20 scores in multiple myeloma patients","volume":"103","author":"Sully","year":"2019","journal-title":"Eur J Haematol"},{"key":"2025121407452284000_10.1.e033176.47","doi-asserted-by":"publisher","DOI":"10.1111\/jep.12629"},{"key":"2025121407452284000_10.1.e033176.48","doi-asserted-by":"publisher","DOI":"10.1111\/j..2002.384.doc.x"},{"key":"2025121407452284000_10.1.e033176.49","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780141709"},{"key":"2025121407452284000_10.1.e033176.50","unstructured":"Macmillan Cancer Support . Prehabilitation for people with cancer: principles and guidance for prehabilitation within the management and support of people with cancer. England, 2019."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2019-033176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T15:45:31Z","timestamp":1765727131000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2019-033176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,1,29]]},"published-print":{"date-parts":[[2020,1]]}},"alternative-id":["10.1136\/bmjopen-2019-033176"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2019-033176","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}